Boehringer Ingelheim Corporation Release: New Pradaxa® Clinical Study To Explore Practical Management Of Patients With Atrial Fibrillation Undergoing Ablation

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

INGELHEIM, Germany--(BUSINESS WIRE)--For media outside of the U.S., the UK & Canada only. Boehringer Ingelheim today announces a new study of Pradaxa® (dabigatran etexilate) in patients with atrial fibrillation (AF). The RE-CIRCUIT™ study will investigate the safety and efficacy of uninterrupted anticoagulant treatment with Pradaxa® in patients with AF who undergo ablation.5 Results of the study are expected in 2016.

Help employers find you! Check out all the jobs and post your resume.

Back to news